Thursday, October 3 – 08:15 AM ET

Gordon Mathieson Invited Lecture
Dr. Gabor Kovacs

Gabor G. Kovacs MD PhD is Professor of Neuropathology and Neurology at the University of Toronto. He is Consultant Neuropathologist and Neurologist at the University Health Network (UHN) and a Principal Investigator at the Tanz Centre for Research in Neurodegenerative Disease. Dr. Kovacs is the Co-Director of the Rossy Program for Progressive Supranuclear Palsy Research.

Dr. Kovacs completed his medical training at the Semmelweis University (Budapest, Hungary) where he specialized in Neurology and Neuropathology and obtained a PhD in Neuroscience. From 2004 to 2007, he was the Head of the Department of Neuropathology at the National Institute of Psychiatry and Neurology in Budapest, Hungary. From 2007 to 2019, he was an Associate Professor at the Institute of Neurology at the Medical University of Vienna, Austria. He was the leader of the Hungarian (2004-2019) and Austrian (2011-2019) Reference Center for Human Prion Diseases. Dr. Kovacs has also trained at Indiana University (2007) and University of Pennsylvania (2016 and 2017) as a visiting professor/scholar. His major research interest is the neuropathology of neurodegenerative diseases to identify early biomarkers and therapy targets. His achievements
include first descriptions, characterization and pathogenic elucidation of several poorly recognized neurological diseases, including frontotemporal dementia with globular glial inclusions and ageing-related tau-astrogliopathy (ARTAG). He coordinated a study and described the sequential distribution of tau pathology in progressive supranuclear palsy, which allows staging of disease. In addition, Dr. Kovacs has made fundamental advances in the pathogenic, genetic, neuropathologic and epidemiologic studies on human tau, alpha-synuclein and prion diseases.

Title: Update Of Tau-related Conditions

Assemblies of the microtubule-associated protein tau characterise many neurodegenerative proteinopathies. Electron cryo-microscopy has revealed the structures of tau protofilaments and the propagation of tau assemblies has been demonstrated. This is essential for the classification and diagnosis of taurelated conditions. The presentation provides an overview of conditions of various aetiologies and with disparate clinical symptoms that are associated with the pathological accumulation of assembled tau.

Learning Objectives:

  1. Understand the fundementals of disease classification
  2. Describe the main tauopathy forms
  3. Describe age-related tau pathologies

Target audience
Pathologists
Residents
Medical Students
CanMEDS Roles
Medical Expert (the integrating role)

COI Disclosure:

I have a relationship with a for-profit and/or a not-for-profit organization to disclose. Indicate the organization(s) with which you have/had a relationship
over the previous two years and briefly describe the nature of that relationship.
Any direct financial payments including receipt of honoraria:
Name of for-profit or not-for-profit organization(s) : Parexel
Description of relationship(s) : Advisor/Consultant
Funded grants or clinical trials:
Name of for-profit or not-for-profit organization(s) : Rossy Family Foundation
Description of relationship(s) : Research funding
Patents on a drug, product or device:
Name of for-profit or not-for-profit organization(s) : 5G4 synuclein antibody
Description of relationship(s) : Shared patent

Friday, October 4 – 09:45 AM ET

Invited Lecture
Dr. Uri Tabori

Bio to come

Title: Clinical implications of molecular neuropathology in the genomic era. An oncologist view

Learning Objectives:

  1. tbd

 

COI Disclosure:

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose.

Friday, October 4 – 9:45 AM ET

Invited Lecture
Dr. Mary Jane Lim-Fat, University of Toronto

Dr Mary Jane Lim-Fat is a neuro-oncologist at Sunnybrook Health Sciences Centre and a clinician investigator at the University of Toronto. She co-leads the Canadian Adolescent and Young Adult Neuro-Oncology Network and is the Young Investigator representative on the Society for Neuro-Oncology Board of Directors. Dr Lim-Fat’s research interest are on precision oncology for brain tumor patients, in particular young adults.

TBC
Experiences with the introduction of competency based medical training in Anatomic Pathology

Description to come

Learning Objectives:

1. TBC
2. TBC
3. TBC

COI Disclosure:

TBC

Get Presentation

Presentation to come

Title: Clinical Application Of Molecular Testing In Adult Brain Tumors

This presentation will describe how molecular testing has impacted diagnosis and clinical management of brain tumors in adults. The most recent therapeutic updates based on molecular profiling of adult gliomas will be specifically reviewed, focusing on glioblastoma and IDH-mutant tumors.

Learning Objectives:

  1. describe how molecular testing is used in the diagnosis of adult brain tumors
  2. describe how molecular testing can be used to inform therapies in adult brain tumors
  3. understand how molecular testing has shaped the new standard of care for gliomas

Target audience
Pathologists
Residents
Medical Students
CanMEDS Roles
Medical Expert (the integrating role)
Collaborator
Health Advocate
Scholar
Professional 

COI Disclosure:

I have a relationship with a for-profit and/or a not-for-profit organization to disclose. Indicate the organization(s) with
which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.
Any direct financial payments including receipt of honoraria
Name of for-profit or not-for-profit organization(s) : Cancer Care Ontario, Servier, Novocure
Description of relationship(s) : Consultancy
Funded grants or clinical trials
Name of for-profit or not-for-profit organization(s) : Brain Cancer Canada, Brain Tumor Foundation of Canada
Description of relationship(s) : Grant

Saturday, October 5 – 8:00 AM ET

David Robertson Guest Lecture
Dr. Arnold Kriegstein, UCSF

Dr. Arnold Kriegstein received his BA from Yale University and his MD and PhD degrees from New York University in 1977. He subsequently completed residency training in Neurology at the Brigham and Women’s, Children’s, and Beth Israel Hospitals in Boston. He held academic appointments at Stanford, Yale, and Columbia Universities before joining the Neurology Department at UC San Francisco In 2004. He was the Founding Director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF. Dr. Kriegstein’s research focuses on the way in which neural stem and progenitor cells in the embryonic brain produce neurons, and ways in which this information can be used for cell-based therapies to treat diseases of the nervous system. He is a co-founder of Neurona Therapeutics which is beginning a clinical trial using cell therapy to treat epilepsy..

Title: Transcriptomic cytoarchitecture of the brain

Development of the human cerebral cortex will be described in terms of cellular components and molecular signaling pathways. New insights into the origins of autism, schizophrenia, depression, and glioblastoma will be described.

Learning Objectives:

  1. know human-specific features of brain development
  2. identify cell and age specific vulnerabilities for autism and schizophrenia.
  3. know the embryonic origins of glioblastoma.
  4. appreciate how single cell gene expression and spatial transcriptomics can inform studies of brain development and neurodevelopmental

Target audience
Pathologists
Residents
Medical Students
CanMEDS Roles
Medical Expert (the integrating role)
Communicator
Collaborator
Leader
Health Advocate
Scholar
Professional

COI Disclosure:

I have a relationship with a for-profit and/or a not-for-profit organization to disclose. Indicate the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.
Any direct financial payments including receipt of honoraria
Name of for-profit or not-for-profit organization(s) : Neurona Therapeutics
Description of relationship(s) : Consultant, equity holder
Patents on a drug, product or device
Name of for-profit or not-for-profit organization(s) : University of California, San Francisco
Description of relationship(s) : Employee

Saturday, October 5 – 08:50 AM ET

Jerzy Olszewski Guest Lecture
Dr. Maryam Faiz, University of Toronto

Dr. Maryam Faiz was born outside Washington DC. She completed her undergrad at the University of St Andrews in the UK. She then went to Barcelona (mostly for soccer) but also received her PhD from the Autonomous University of Barcelona. Tired of all the fun, beach and sun, she then moved to Sweden and trained with Milos Pekny at the University of Goteborg. She managed to then make her way somewhere even colder and worked under Dr. Andras Nagy at the Lunenfeld-Tanenbaum Research Institute in Toronto. She started her lab in this city at the University of Toronto in 2017.

She now is Mom to two mini-Canadians who are “onboarding her” under the guise of teaching her to ice skate and canoe. Every day, after packing their lunches and battling them to put on their shoes, she heads to the lab to study astrocytes. She believes these cells may hold the key to brain repair. Her lab is interested in astrocyte heterogeneity and how it is established, the roles of astrocytes in the injured/diseased brain, and how this knowledge can inform future therapeutic interventions.

Today, she will talk to you about a study of astrocyte diversity after an ischemic injury. Spoiler alert: she is also fascinated by the gut-brain axis and how
the gut can mediate recovery from brain injury, which, stay tuned, may turn out to involve astrocytes! 

Title: An Integrated Single-cell And Spatial Transcriptomics Approach Reveals The Heterogeneity Of The Astrocyte Response To Stroke

Astrocytes undergo molecular, morphological, and functional changes after stroke, termed reactivity, which influence disease outcomes. I will present our recent work examining the diversity of the astrocyte response in stroke using multiscale tools: 10X Visium spatial transcriptomics to establish the molecular signatures of the ischemic cortex over time post-stroke; 10X Chromium to study the transcriptional heterogeneity of astrocytes; and evDISCO to perform a high-resolution, spatially resolved analysis of individual astrocyte transcriptomes and proteomes at various distances from the infarct. These datasets uncovered diverse astrocyte states in stroke, influenced by time and proximity to the infarct. In particular, we identified a ‘proximal’ [to infarct] astrocyte characterized by gene expression related to lipid metabolism and signaling, including Fabp5. I will also share preliminary work on how these FABP5+ astrocytes are regulated and their roles in stroke recovery.

Learning Objectives:

  1. Identify diverse astrocyte states in stroke
  2. Apply single and spatial sequencing technologies to study astrocytes

Target audience
Pathologists
Residents
Medical Students
Other – Write In (Required): Basic scientists
CanMEDS Roles
Scholar

COI Disclosure:

I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose.

Saturday, October 5 – 10:00 AM ET

Invited Lecture
Dr. Brittany Dugger, UC Davis School of Medicine

Dr. Dugger is overwhelmingly excited and honored to contribute fundamental knowledge to precision medicine approaches to aid in creating better biomarkers, therapies, and models of human diseases for all individuals.
Throughout her career she has led, enabled, and enhanced many cross disciplinary projects, resulting in more than 90 peer-reviewed manuscripts and numerous private, state, and federally funded grants. Dr. Dugger earned her Bachelor of Science from Michigan State University. She went on to obtain her PhD from Mayo Clinic Graduate School, where she became fascinated by the selective vulnerability of neuropathologies and disease heterogeneity. She completed a postdoctoral fellowship, being promoted to an independent staff scientist at Banner Sun Health Research Institute, aiding in a research-based human autopsy program. In 2015, she was recruited to serve as the neuropathology core leader for academic and drug discovery groups at the University of California San Francisco. In 2017, she joined the Department of Pathology and Laboratory Medicine at the University of California, Davis (UCD), and is currently an associate professor with tenure. In addition to running her own laboratory, she is the neuropathology core leader of the UCD-Alzheimer’s Disease Research Center (ADRC) and department Liaison for the Women in Medical and Health Sciences. Dr. Dugger is involved in many national endeavors, including the College of American Pathologists Neuropathology Committee and is the chair of the ADRC Neuropathology Core Steering Committee. She has extensive expertise in cross disciplinary dialog development and maintenance, data harmonization/amalgamation, mentorship, sponsorship, advocacy, and administrative execution and oversight.

Title: Digital pathology applications in neurodegeneration

We are in an age of digital pathology and many would like to implement processes into their workflow. In this talk Dr. Dugger aims to provide advice from the “digital” road including incorporating machine learning tools into
neurodegenerative disease workflows. Dr. Dugger will also touch upon the value of cross-disciplinary dialogs and current benchmarks in digital pathology.

Learning Objectives:

  1. Describe a basic machine learning workflow in neuropathology
  2. Understand digital pathology benchmarks across universities

Target audience
Pathologists
Residents
Medical Students
CanMEDS Roles
Communicator
Collaborator
Leader
Scholar

COI Disclosure:

I have a relationship with a for-profit and/or a not-for-profit organization to disclose. Indicate the organization(s) with
which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.
Any direct financial payments including receipt of honoraria
Name of for-profit or not-for-profit organization(s) : University of Southern California
Description of relationship(s) : Alzheimer’s Disease Center External Advisory Board Member
Membership on advisory boards or speakers’ bureaus
Name of for-profit or not-for-profit organization(s) : College of American Pathologists
Description of relationship(s) : Neuropathology Committee member
Funded grants or clinical trials
Name of for-profit or not-for-profit organization(s) : National Institutes of Health
Description of relationship(s) : Principle Investigator/Co-investigator on numerous grants

Saturday, October 5 – 10:50 AM ET

Invited Lecture
Dr. Sandra Camelo-Piragua, University of Michigan

Dr. Sandra Camelo-Piragua is a Clinical Professor of Pathology and the Neuropathology Fellowship Program Director at the University of Michigan. She obtained her M.D. from Universidad de Antioquia, Medellin, Colombia. This was followed by a postdoctoral research fellow at the Laboratory of Transcriptional and Immune Regulation for Neurodegenerative diseases at Brigham and Women’s Hospital, Boston, MA. She obtained her AP/CP training at Baystate Medical Center, Western Campus of Tufts Medical School, Springfield, MA.
This was followed by a Neuropathology fellowship at Massachusetts General Hospital, Boston, MA. She joined the clinical faculty at University of Michigan in 2010. Her clinical interests include neoplastic and non-neoplastic conditions of the CNs, molecular classification of brain tumors, and neuromuscular conditions affecting peripheral nerves and muscles in adult and pediatric population.

Her academic interest focuses on the implementation of telepathology, non-destructive optical imaging technologies, ex-vivo microscopy, and image analysis. Dr. Camelo-Piragua is an active member of AANP, serving as Vice-President for 2025. She is also member of Digital and Computational Pathology Committee at the College of American Pathologists.

Title: Digital pathology applications in neuro-oncology

This presentation will provide an overview of the uses of digital pathology in clinical and research settings. Emphasis will be placed on the potential added value of digital pathology on the clinical care of neuro-oncologic patients. We will discuss the use and integration of artificial intelligence tools in digital pathology, including its benefits, consideration for implementation and limitations.

Learning Objectives:

  1. Discuss research and potential clinical applications of digital pathology
  2. Describe the role of pathologists in the care of patients with CNS tumors
  3. Identify opportunities and limitations to incorporate artificial intelligence tools in digital pathology

Target audience
Pathologists
Residents
Medical Students
Other – Write In (Required): Neurosurgeons, neuro-oncologists
CanMEDS Roles
Medical Expert (the integrating role)
Scholar
Professional

COI Disclosure:

I have a relationship with a for-profit and/or a not-for-profit organization to disclose. Indicate the organization(s) with which you
have/had a relationship over the previous two years and briefly describe the nature of that relationship.
Any direct financial payments including receipt of honoraria
Name of for-profit or not-for-profit organization(s) : Cambridge University Press
Description of relationship(s) : Book royalties
All other investments or relationships that could be seen by a reasonable, well- informed participant as having the potential
to influence the content of the educational activity
Name of for-profit or not-for-profit organization(s) : Invenio
Description of relationship(s) : Ad-Hoc Non-paid consultant for image quality analysis

Saturday, October 5 – 11:40 AM ET

Invited Lecture
Dr. Matthew Cecchini, Western University

Dr. Matthew Cecchini is an Associate Professor of Pathology at London Health Sciences Centre and Western University. He completed his anatomical pathology training at Western University, followed by a fellowship in pulmonary pathology at Mayo Clinic. Dr. Cecchini specializes in digital pathology and AI, focusing on integrating advanced technologies like AI-driven image analysis to enhance diagnostics and patient care. He collaborates across various fields to drive innovation in pathology and is dedicated to educating and mentoring future pathologists.

Title: Optimizing Digital Pathology with AI: Strategic Approaches for Modern Clinical Practice

This presentation will explore the critical role of digital pathology transformation in enabling the effective utilization of emerging digital pathology tools, including image analysis and AI-driven technologies. By transitioning to a digital environment, pathology practices can unlock the potential of advanced tools that enhance diagnostic accuracy and streamline workflows. The presentation will outline strategic approaches to deploying image analysis and AI tools that augment pathologist workflows, improving efficiency and patient outcomes. Additionally, it will discuss how AI and large language models (LLMs) can be leveraged to support both clinical and non-clinical tasks, extending their impact beyond traditional pathology to other areas of healthcare. By embracing these technologies, pathology practices can position themselves at the forefront of innovation, driving improvements in patient care and operational excellence.

Learning Objectives:

  1. Outline key considerations in the integration of AI technology within clinical pathology practices.
  2. Identify strategic opportunities for incorporating AI into existing clinical practices.
  3. Recognize the potential benefits of AI
  4. Discuss the role of digital pathology as a prerequisite for deploying AI tools in clinical practice.

Target audience
Pathologists
Residents
Medical Students
CanMEDS Roles
Medical Expert (the integrating role)
Communicator
Collaborator
Leader
Health Advocate
Scholar
Professional

COI Disclosure:

I have a relationship with a for-profit and/or a not-for-profit organization to disclose. Indicate the organization(s) with
which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.
Any direct financial payments including receipt of honoraria
Name of for-profit or not-for-profit organization(s) : Merck, Astra Zeneca, Roche, Amgen and Eli Lilly
Description of relationship(s) : Speaker Honoria
Membership on advisory boards or speakers’ bureaus
Name of for-profit or not-for-profit organization(s) : Astra Zeneca Eli Lilly
Description of relationship(s) : Ad board for Ki67 and digital pathology
Funded grants or clinical trials
Name of for-profit or not-for-profit organization(s) : Eli Lilly and Merck
Description of relationship(s) : unrestricted research grants for Ki67 implementation and PD-L1 reporting
Patents on a drug, product or device
Name of for-profit or not-for-profit organization(s) : Tenomix
Description of relationship(s) : Partial owner of patent for ultrasound based device to detect lymph nodes in colon cancer